Wells Fargo lowered the firm’s price target on Baxter to $40 from $44 and keeps an Equal Weight rating on the shares. The firm says Baxter’s 2024 guidance raise and management’s view that the company has turned the corner are encouraging, positioning it on solid ground for 2025. Renal separation uncertainty still an overhang, Wells adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: